Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study

Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study

Abstract Background Camptothecin (CPT) and its derivatives are currently used as second- or third-line treatment for patients with endocrine-resistant breast cancer (BC). These drugs convert nuclear enzyme DNA topoisomerase I (TOP1) to a cell poison with the potential to damage DNA by increasing the...

Full description

Bibliographic Details
Main Authors: Cinzia Tesauro, Anne Katrine Simonsen, Marie Bech Andersen, Kamilla Wandsoe Petersen, Emil Laust Kristoffersen, Line Algreen, Noriko Yokoyama Hansen, Anne Bech Andersen, Ann Katrine Jakobsen, Magnus Stougaard, Pavel Gromov, Birgitta R. Knudsen, Irina Gromova
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Cancer
Subjects:
Breast cancer
Breast cancer cell lines
Breast tumor subtypes
Topoisomerase I
Camptothecin sensivity
Online Access:https://doi.org/10.1186/s12885-019-6371-0

Internet

https://doi.org/10.1186/s12885-019-6371-0

Similar Items